0.380
-0.01 (-3.77%)
| Previous Close | 0.395 |
| Open | 0.380 |
| Volume | 31,100,489 |
| Avg. Volume (3M) | 109,483,325 |
| Market Cap | 35,613,624 |
| Price / Sales | 122.70 |
| Price / Book | 8.48 |
| 52 Weeks Range | |
| Earnings Date | 15 May 2025 |
| Operating Margin (TTM) | -20,952.04% |
| Diluted EPS (TTM) | -1.23 |
| Total Debt/Equity (MRQ) | 22.79% |
| Current Ratio (MRQ) | 2.12 |
| Operating Cash Flow (TTM) | -14.67 M |
| Levered Free Cash Flow (TTM) | -6.95 M |
| Return on Assets (TTM) | -76.74% |
| Return on Equity (TTM) | -201.87% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Drug Manufacturers - Specialty & Generic (US) | Bullish | Mixed |
| Drug Manufacturers - Specialty & Generic (Global) | Bullish | Mixed | |
| Stock | Incannex Healthcare Inc. | - | - |
AIStockmoo Score
| Analyst Consensus | 2.0 |
| Insider Activity | NA |
| Price Volatility | 0.5 |
| Technical Moving Averages | 5.0 |
| Technical Oscillators | 2.0 |
| Average | 2.38 |
|
Incannex Healthcare Inc is a clinical stage pharmaceutical company developing medical cannabis products for the treatment of Obstructive Sleep Apnea (OSA), Traumatic Brain Injury (TBI)/Concussion, Rheumatoid Arthritis, Inflammatory Bowel Disease, and Inflammatory Lung Conditions. The company has an Australian license to import, export, and distribute medicinal cannabis products and has launched a line of cannabinoid products. The Company operates and manages its business as one reportable and operating segment, which is the Research and Development of the use of psychedelic medicine and therapies. |
|
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Investment Style | Small Core |
| % Held by Insiders | 26.14% |
| % Held by Institutions | 8.65% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Revisor Wealth Management Llc | 30 Jun 2025 | 14,042 |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |